Press release content from Newswire. The AP news staff was not involved in its creation.
Waynes Announces Largest Acquisition With Purchase of Kirkland’s Pest Control
April 12, 2021 GMT
Photo from left to right - Shawn Hollis (President) Allen Kirkland & Kirkland s Leadership, Ryan Tate (VP Operations - North Region)
Photo from left to right - Shawn Hollis (President) Allen Kirkland & Kirkland s Leadership, Ryan Tate (VP Operations - North Region)
BIRMINGHAM, Ala. - April 12, 2021 - ( Newswire.com )
Birmingham-based Waynes Pest Control today announces continued strengthening of its positions in Tennessee and North Alabama with the acquisition of Kirkland’s Pest Control. Headquartered in Fayetteville, TN, Kirkland’s has been serving Middle to East Tennessee and North Alabama for over four decades. Kirkland’s operates multiple locations including Fayetteville, Huntsville, Chattanooga, and Sevierville. Focused on aggressive growth, this is Waynes’ fifth acquisition in th
Press release content from Business Wire. The AP news staff was not involved in its creation.
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 12, 2021
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately.
“We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. “As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus decades of clinical and development experience, as well
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biofrontera reports results for the 2020 financial year
Biofrontera AGApril 12, 2021 GMT
Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time, the Company provided an overview of current operational and clinical developments.
Key financial figures FY2020
Revenue decreased by 3% to EUR 30.3 million compared to EUR 31.3 million in 2019;
Loss from operations amounted to EUR 7.6 million compared to a loss of EUR 23.4 million in 2019;